RockGarden Announces Financing to Expand Cannabis Production Facility

CARLETON PLACE, Ontario, Aug. 18, 2017 (GLOBE NEWSWIRE) -- RockGarden (Company), a late stage applicant under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), announced that it has launched an $8.2 million financing to expand its current production facility. RockGarden intends to use the proceeds raised by this financing to immediately complete … [Read more...]

Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuing this press release to provide clarification of the press release issued August 14, 2017.  The following sentences in the previous press release require modification to ensure clarity of meaning: “The … [Read more...]

American Health Council Names William P. Dillon, M.D. to Education Board

NEW YORK, Aug. 18, 2017 (GLOBE NEWSWIRE) -- Dr. William P. Dillon, Associate Professor of Obstetrics and Gynecology at SUNY Buffalo, has been selected to join the Education Board at the American Health Council. He will be sharing his knowledge and expertise in Medicine, Biology, Chemistry, Obstetrics & Gynecology, Maternal Fetal Medicine, and High-Risk Pregnancies. Dr. … [Read more...]

Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results

- Clinical Pipeline Expands to Include TransCon PTH while Phase 3 Program for TransCon Growth Hormone Advances - - Conference Call Today at 8:00 a.m. Eastern Time - COPENHAGEN, Denmark, Aug. 18, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical … [Read more...]

Kane Biotech Announces Second Closing of Private Placement Offering and Resignation of Director

WINNIPEG, Manitoba, Aug. 18, 2017 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced that it has completed the second closing of its previously announced private placement offering (the "Offering") of units (“Units”) at a price of $0.12 per Unit effective August 17, 2017. At the second closing, the Company issued 1,100,000 … [Read more...]